Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y5J7
UPID:
TIM9_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y5J7; B2R584
Background:
The Mitochondrial import inner membrane translocase subunit Tim9 plays a crucial role in mitochondrial functionality, aiding in the import and insertion of multi-pass transmembrane proteins into the mitochondrial inner membrane. It serves as a chaperone, facilitating the transfer of beta-barrel precursors to the mitochondrial outer membrane's sorting and assembly machinery.
Therapeutic significance:
Understanding the role of Mitochondrial import inner membrane translocase subunit Tim9 could open doors to potential therapeutic strategies.